Table 2.
Knowledge of HPV infection, vaccine and cervical cancer among GPs and public health nurses in Northern Norway: Proportions (%) giving correct answer to each question (95% CI).a
| GPs (n = 121) % | Public healthnurses (n= 99) % | pb | Correct answer | |
|---|---|---|---|---|
| What percentage of cervical cancer is caused by HPV?d | 55 (45–65) | 37 (28–46) | 0.008 | 100%c |
| What is the lifetime risk of a sexually active person getting HPV infectiond | 26 (17–35) | 35 (27–44) | 0.117 | 70% |
| What percentage of cervical cancer do the genotypes HPV16 and 18 cause?d | 44 (35–53) | 58 (48–68) | 0.042 | 70% |
| How many cases of cervical cancer do you think we have in Norway per year? | 43 (33–53) | 64 (56–73) | 0.002 | 300 |
| How many operations for precancerous lesions are performed in Norway per year? | 32 (23–39) | 56 (46–66) | <0.000 | 3000 |
| Which vaccine was chosen for the programme in Norway? | 33 (25–41) | 86 (79–93) | <0.000 | 4-valent, against genotypes 6, 11, 16 and 18 |
| What is the price of one dose of this vaccine? | 41 (32–50) | 68 (59–77) | <0.000 | NOK 1200 |
a
One year after the introduction of the HPV vaccine in the vaccination programme.
b
Significant differences between GPs and PHN in bold, p value based on the Chi square test.
c
90–100% accepted as correct answer.
d
Used as independent variables in logistic regression model(s).